By Regulatory Approvals — FDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancer The Clinical Trial Vanguard
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 19, 2026.